Overview
The aim of this study is to describe patients' satisfaction with Patient Support Program (Balance Program), Quality of Life and depression symptoms, dosing pattern, disease symptoms, adverse events and nintedanib discontinuation (both permanent and non-permanent) from study inclusion to 12 months of follow-up.
Eligibility
Inclusion criteria
- Adults (≥18 years old at baseline).
- Patients included in the Patient Support Program (PSP) Balance Program.
- Ability to read and speak Spanish correctly according to the investigator criteria.
- Agree to participate and signing informed consent at baseline.
Exclusion criteria
- Suspicion or diagnosis of any relevant cognitive impairment at the discretion of the investigator.